QMSMEDI QMS Medical Allied Services Q2 FY26 results (Jul–Sep 2025) and concall
QMS Medical Allied Services reported robust revenue growth for Q2 and H1 FY26, driven by strong performance in both product and service verticals. While EBITDA margins saw a slight decline due to strategic investments and pricing adjustments, management expects normalization within a year. The company is focused on expanding its patient support programs, leveraging technology, and integrating Saarathi Healthcare to capitalize on India's evolving healthcare landscape.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 26.0%, net profit up 1.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 33 | 39 | 42 | 42 | 41 +26% |
| EBITDA | 5 | 5 | 8 | 6 | 6 +15% |
| Net profit | 3 | 2 | 3 | 3 | 3 +1% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
